ZLAB(再鼎医药 (Zai Lab)) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $144.31M | $215.04M | $266.72M | $398.99M | $460.16M |
| 毛利润 | $92.07M | $141.02M | $170.90M | $251.87M | $269.64M |
| 营业利润 | −$700.06M | −$404.36M | −$366.57M | −$282.12M | −$229.43M |
| 净利润 | −$704.47M | −$443.29M | −$334.62M | −$257.10M | −$175.54M |
| 经营现金流 | −$549.23M | −$367.64M | −$198.18M | −$214.87M | −$150.79M |
| 自由现金流 | −$567.53M | −$392.23M | −$205.39M | −$220.53M | −$158.89M |
| 摊薄每股收益 | $-0.76 | $-0.46 | $-0.35 | $-0.26 | $-0.16 |